Cambridge Investment Research Advisors
ALNY icon

Cambridge Investment Research Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$353K Sell
1,173
-754
-39% -$227K ﹤0.01% 3299
2026
Q1 		$638K Sell
1,927
-1,105
-36% -$376K ﹤0.01% 2586
2025
Q4 		$1.21M Sell
3,032
-148
-5% -$65.5K ﹤0.01% 1946
2025
Q3 		$1.45M Buy
3,180
+1,796
+130% +$731K ﹤0.01% 1759
2025
Q2 		$451K Buy
1,384
+595
+75% +$165K ﹤0.01% 2636
2025
Q1 		$213K Buy
+789
New +$203K ﹤0.01% 3155
2023
Q1 		– Sell
-849
Closed -$202K – 3152
2022
Q4 		$202K Buy
+849
New +$181K ﹤0.01% 2744
2022
Q2 		– Sell
-3,285
Closed -$536K – 3049
2022
Q1 		$536K Buy
3,285
+9
+0.3% +$1.37K ﹤0.01% 2040
2021
Q4 		$556K Sell
3,276
-56
-2% -$10.4K ﹤0.01% 2023
2021
Q3 		$629K Sell
3,332
-1,212
-27% -$227K ﹤0.01% 1870
2021
Q2 		$770K Buy
4,544
+95
+2% +$13.9K ﹤0.01% 1730
2021
Q1 		$628K Buy
+4,449
New +$670K ﹤0.01% 1725
2015
Q3 		– Sell
-1,750
Closed -$210K – 1451
2015
Q2 		$210K Buy
+1,750
New +$209K 0.01% 1264
2013
Q4 		– Sell
-3,441
Closed -$220K – 1237
2013
Q3 		$220K Buy
+3,441
New +$172K 0.01% 985

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cambridge Investment Research Advisors's ALNY Position: Q2 2026 in Review

Cambridge Investment Research Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 39% in Q2 2026, selling an estimated $227K and leaving 1,173 shares worth $353K. The position accounts for ﹤0.01% of the portfolio, ranked #3299.

Cambridge Investment Research Advisors first reported a position in ALNY in Q3 2013 and has held it in 14 quarters since. The position peaked at $1.45M in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Cambridge Investment Research Advisors held 1,173 shares of Alnylam Pharmaceuticals worth $353K as of Q2 2026.
  • Cambridge Investment Research Advisors sold 754 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $227K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3299 holding.
  • Cambridge Investment Research Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 14 quarters since.
  • Cambridge Investment Research Advisors's Alnylam Pharmaceuticals position peaked at $1.45M in Q3 2025.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.